|
Clinical Trial of ABC294640 in Patients with Refractory Multiple Myeloma
|
5R44CA199767-03
|
$653,219
|
$653,219
|
SMITH, CHARLES
|
APOGEE BIOTECHNOLOGY CORPORATION
|
|
Targeting c-Myc and Proteasome Inhibitor Resistance in Multiple Myeloma
|
1R01CA212119-01A1
|
$580,951
|
$580,951
|
CHEN, YUAN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S1
|
$73,297
|
$2,199
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S2
|
$124,999
|
$3,750
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
5P30CA033572-34
|
$2,446,682
|
$73,400
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-04S1
|
$2,088,480
|
$52,212
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-04
|
$11,145,123
|
$278,628
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S1
|
$118,875
|
$5,944
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S2
|
$60,000
|
$3,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S3
|
$200,000
|
$10,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S4
|
$145,821
|
$7,291
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-27
|
$4,895,515
|
$244,776
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
3U10CA180853-04S1
|
$76,498
|
$1,912
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-04
|
$1,188,450
|
$29,711
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Convergence of MicroRNAs and p53 Signaling in Multiple Myeloma: Environmental Co
|
5R01CA138688-09
|
$334,629
|
$334,629
|
LI, YONG
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Targeting macrophages to sensitize myeloma to immune checkpoint blockade
|
1R01CA214811-01
|
$328,888
|
$328,888
|
YI, QING
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
A novel T-cell subset able to kill relapsed cancers
|
5R01CA200539-02
|
$362,569
|
$362,569
|
YI, QING
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Elucidating the role of microRNAs in the initiation of multiple myeloma
|
5R00CA172292-05
|
$248,999
|
$248,999
|
ZHAO, JIANJUN
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Validating Rapid Microfluidic Isolation of Personalized Aptamers for Monitoring Minimal Residual Disease in Multiple Myeloma
|
5R33CA196470-02
|
$390,115
|
$390,115
|
LIN, QIAO
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
Cancer Center Support Grant
|
3P30CA013696-43S1
|
$120,000
|
$2,400
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S2
|
$60,000
|
$1,200
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S3
|
$118,652
|
$2,373
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S4
|
$199,541
|
$3,991
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-43
|
$3,792,720
|
$75,854
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
HAUSP inhibitors in p53-wild type and p53-mutant tumors
|
5R01CA193890-03
|
$366,000
|
$91,500
|
GU, WEI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The Role of MMP13 in Multiple Myeloma Bone Disease
|
5R01CA175313-04
|
$331,098
|
$331,098
|
LENTZSCH, SUZANNE
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
SPORE in Multple Myeloma
|
5P50CA100707-15
|
$2,300,000
|
$2,300,000
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications
|
5R01CA050947-25
|
$301,545
|
$301,545
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple Myeloma
|
5R01CA207237-02
|
$395,166
|
$395,166
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-52S2
|
$60,000
|
$2,400
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-52S3
|
$100,000
|
$4,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Stapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human Cancer
|
5R50CA211399-02
|
$264,110
|
$66,028
|
BIRD, GREGORY
|
DANA-FARBER CANCER INST
|
|
USP7 inhibitors for the treatment of multiple myeloma
|
1R01CA211681-01
|
$504,721
|
$504,721
|
BUHRLAGE, SARA
|
DANA-FARBER CANCER INST
|
|
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
|
5U10CA180867-04
|
$1,302,199
|
$32,555
|
BURSTEIN, HAROLD
|
DANA-FARBER CANCER INST
|
|
Validating the eCyPA/CD147 signaling complex for myeloma therapy
|
5R01CA196783-03
|
$394,823
|
$394,823
|
CARRASCO, RUBEN
|
DANA-FARBER CANCER INST
|
|
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase.
|
1R01CA214608-01
|
$426,818
|
$426,818
|
FISCHER, ERIC
|
DANA-FARBER CANCER INST
|
|
Stroma-mediated clonal evolution in Multiple Myeloma
|
5R01CA181683-04
|
$353,770
|
$353,770
|
GHOBRIAL, IRENE
|
DANA-FARBER CANCER INST
|
|
(PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS)
|
5R01CA205954-02
|
$438,499
|
$438,499
|
GHOBRIAL, IRENE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
2P30CA006516-52
|
$11,592,798
|
$463,712
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-52S1
|
$112,500
|
$4,500
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Functional and biologic significance of deacetylase3 inhibition in myeloma
|
5R01CA178264-04
|
$353,291
|
$353,291
|
HIDESHIMA, TERU
|
DANA-FARBER CANCER INST
|
|
Determining the mutational landscape of circulating multiple myeloma cells
|
5K08CA191026-03
|
$177,120
|
$177,120
|
LOHR, JENS
|
DANA-FARBER CANCER INST
|
|
Humanized bone marrow-like model to study patient-derived myeloma xenografts
|
5R01CA196664-02
|
$541,945
|
$541,945
|
MITSIADES, CONSTANTINE
|
DANA-FARBER CANCER INST
|
|
Integrative Oncogenomics of Multiple Myeloma
|
2P01CA155258-06
|
$2,086,676
|
$2,086,676
|
MUNSHI, NIKHIL
|
DANA-FARBER CANCER INST
|
|
Improving Hospice Use for Patients with Blood Cancers
|
1K08CA218295-01
|
$176,867
|
$44,217
|
ODEJIDE, OREOFE
|
DANA-FARBER CANCER INST
|
|
Targeting sphingosine kinase 2 for the treatment of multiple myeloma
|
5R01CA197792-03
|
$363,713
|
$363,713
|
KANG, YUBIN
|
DUKE UNIVERSITY
|
|
Cancer Center Support Grant
|
3P30CA014236-43S1
|
$116,657
|
$1,167
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
|
Cancer Center Support Grant
|
3P30CA014236-43S2
|
$29,688
|
$297
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
|
Cancer Center Support Grant
|
3P30CA014236-43S3
|
$83,246
|
$832
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
|
Cancer Center Support Grant
|
5P30CA014236-43
|
$5,679,062
|
$56,791
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
Total relevant funding to Multiple Myeloma for this search: $60,746,955
|